Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
48.26
-0.70 (-1.43%)
Oct 14, 2025, 3:50 PM EDT - Market open
Avidity Biosciences Employees
Avidity Biosciences had 391 employees as of December 31, 2024. The number of employees increased by 138 or 54.55% compared to the previous year.
Employees
391
Change (1Y)
138
Growth (1Y)
54.55%
Revenue / Employee
$27,440
Profits / Employee
-$1,165,581
Market Cap
6.93B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 391 | 138 | 54.55% |
Dec 31, 2023 | 253 | 67 | 36.02% |
Dec 31, 2022 | 186 | 61 | 48.80% |
Dec 31, 2021 | 125 | 54 | 76.06% |
Dec 31, 2020 | 71 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RNA News
- 1 day ago - Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 - PRNewsWire
- 8 days ago - Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - PRNewsWire
- 4 weeks ago - Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 4 weeks ago - Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - PRNewsWire
- 4 weeks ago - Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha
- 4 weeks ago - Lovesac, Avidity Biosciences, Veritone And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
- 4 weeks ago - Avidity Biosciences, Inc. (RNA) Discusses On Redefining The Treatment Of Duchenne Muscular Dystrophy (Transcript) - Seeking Alpha
- 4 weeks ago - Avidity Biosciences Announces Proposed Public Offering of Common Stock - PRNewsWire